NASDAQ: SKYE
Skye Bioscience Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their SKYE stock forecasts and price targets.

Forecast return on equity

Is SKYE forecast to generate an efficient return?

Company
-275.03%
Industry
90.51%
Market
167%
SKYE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SKYE forecast to generate an efficient return on assets?

Company
-194.51%
Industry
28.5%
SKYE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SKYE earnings per share forecast

What is SKYE's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$0.98
Avg 2 year Forecast
-$1.13
Avg 3 year Forecast
-$1.40

SKYE revenue forecast

What is SKYE's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

SKYE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SKYE$0.86N/AN/A
NRSN$0.88$8.50+865.91%Strong Buy
NEUP$5.31$7.00+31.83%Buy
TPST$1.99$11.00+452.76%Buy
LSTA$3.15N/AN/A

Skye Bioscience Stock Forecast FAQ

What is SKYE's earnings growth forecast for 2026-2028?

(NASDAQ: SKYE) Skye Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.

Skye Bioscience's earnings in 2026 is -$55,924,814.On average, 10 Wall Street analysts forecast SKYE's earnings for 2026 to be -$32,731,216, with the lowest SKYE earnings forecast at -$47,104,112, and the highest SKYE earnings forecast at -$20,678,144. On average, 10 Wall Street analysts forecast SKYE's earnings for 2027 to be -$37,728,017, with the lowest SKYE earnings forecast at -$55,936,133, and the highest SKYE earnings forecast at -$20,327,667.

In 2028, SKYE is forecast to generate -$46,756,973 in earnings, with the lowest earnings forecast at -$70,001,944 and the highest earnings forecast at -$23,481,960.

If you're new to stock investing, here's how to buy Skye Bioscience stock.

What is SKYE's revenue growth forecast for 2026-2028?

(NASDAQ: SKYE) Skye Bioscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.07%.

Skye Bioscience's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast SKYE's revenue for 2026 to be $0, with the lowest SKYE revenue forecast at $0, and the highest SKYE revenue forecast at $0. On average, 9 Wall Street analysts forecast SKYE's revenue for 2027 to be $0, with the lowest SKYE revenue forecast at $0, and the highest SKYE revenue forecast at $0.

In 2028, SKYE is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SKYE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SKYE) forecast ROA is -194.51%, which is lower than the forecast US Biotechnology industry average of 28.5%.

What is SKYE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SKYE) Skye Bioscience's current Earnings Per Share (EPS) is -$1.41. On average, analysts forecast that SKYE's EPS will be -$0.98 for 2026, with the lowest EPS forecast at -$1.41, and the highest EPS forecast at -$0.62. On average, analysts forecast that SKYE's EPS will be -$1.13 for 2027, with the lowest EPS forecast at -$1.68, and the highest EPS forecast at -$0.61. In 2028, SKYE's EPS is forecast to hit -$1.40 (min: -$2.10, max: -$0.70).

What is SKYE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SKYE) forecast ROE is -275.03%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.